DataMEDS AI, Inc. (MEDS)
| Market Cap | 2.28M -95.6% |
| Revenue (ttm) | 8.02M -78.2% |
| Net Income | -88.28M |
| EPS | -43.73 |
| Shares Out | 3.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,942,834 |
| Open | 0.8731 |
| Previous Close | 0.8702 |
| Day's Range | 0.5525 - 1.0900 |
| 52-Week Range | 0.5525 - 35.5000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About MEDS
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidi... [Read more]
Financial Performance
In 2025, DataMEDS AI's revenue was $23.34 million, an increase of 28.73% compared to the previous year's $18.13 million. Losses were -$101.27 million, 1377.1% more than in 2024.
Financial StatementsNews
DataMEDS AI signs MOU to deploy Health Lives Here mobile application
DataMeds AI (MEDS) announced that it has signed a memorandum of understanding with a Florida-based health maintenance organization, whose name is being withheld at its request, to deploy the Health…
DataMEDS announces termination of second amended and restated letter of intent
DataMeds AI (MEDS) announced that it has terminated the Second Amended and Restated letter of intent dated October 19 with Datavault AI (DVLT), Data Health Partners, or DHP, wholly-owned subsidiary…
DataMEDS AI enters pact for commercial supply of six peptides
DataMeds AI (MEDS) announced that its pharmacy-focused subsidiary Corexa Health has entered into an agreement for commercial supply to bulk drug substance and API of six peptide recommended by the…
DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best prac...
Datavault signs non-binding LOI to acquire 19.9% stake in DataMEDS AI
Datavault AI (DVLT) announced that it has entered into a non-binding letter of intent to acquire a 19.9% equity interest in DataMEDS AI (MEDS) in consideration of an expansion of…
Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and r...
DataMEDS AI enters amended, restated LOI to license, acquire IP
DataMEDS AI (MEDS) has entered into an amended and restated non-binding letter of intent dated October 19 with Datavault (DVLT) AI, Data Health Partners’ wholly-owned subsidiary REBOOT Health AI, Inc....
DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan Lev...
DataMeds Regains Compliance With NASDAQ Listing Standards
TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physica...
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc....
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMED...
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / AC...
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS...
Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature TAMPA, FL / ACCESS Newswire / October 5, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI,...
DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches TAMPA, FL / ACCESS Newswire / October 1, 2...
DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services TAMPA, FL / ACCESS Newswire / September 28, 2026 / Data...
DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit
Interim Co-CEO to Discuss Growing Patient Desire to Own Health Data TAMPA, FL / ACCESS Newswire / September 25, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a ...
DataMEDS AI Unveils New Corporate Website
Updated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement TAMPA, FL / ACCESS Newswire / September 21, 2026 ...
DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked
TAMPA, FL / ACCESS Newswire / September 18, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastruct...
DataMeds AI Inc trading resumes
09:41 EDT DataMeds AI (MEDS) Inc trading resumes
DataMeds AI Inc trading halted, volatility trading pause
09:31 EDT DataMeds AI (MEDS) Inc trading halted, volatility trading pause
This AI stock experienced a 5x rally on Wednesday
DataMeds AI (MEDS) shares ripped higher on Wednesday morning as the company completed its acquisition of Helomics AI cancer diagnostics laboratory and precision oncology contract research organization...
DataMEDS AI acquires Helomics subsidiary from Axe Compute for $1.5M
DataMEDS AI (MEDS) announced that it completed the acquisition of artificial intelligence cancer diagnostics laboratory business Helomics from Axe Compute (AGPU). Under the agreement, DataMEDS acquire...
DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute
Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management PITTSBURGH, PA / ACCESS Newswire / September 15, 2026 / DataMEDS AI, Inc. (NASDA...
Why Is DataMeds AI Stock (MEDS) Up Nearly 200% Today?
DataMeds AI stock was up almost 200% on Tuesday after the company announced a deal with Axe Compute.